In separate treatment trials, one for de novo coronary lesions and the other for in-stent restenosis, a sirolimus-eluting ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis ...

New study results from a large international all-comer population of percutaneous coronary intervention (PCI) candidates ...

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Boston Scientific is conducting a clinical study titled ‘French ...

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB ...

Intermountain Health surgeons have achieved a medical milestone for Utah patients by successfully performing the state’s ...

MicroPort NeuroTech Limited ((HK:2172)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025DynamX® ...

Elixir Medical today announced new landmark clinical results for its DynamX bioadaptor coronary implant system.

Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) ...

SAN FRANCISCO -- The investigational Selution drug-coated balloon (DCB or DEB) edged closer to primetime in percutaneous ...